Organization (Industry)
AtriCure, Inc.
ClinicalTrials.gov lists AtriCure, Inc. as lead sponsor of 32 trials. It has 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers AtriCure, Inc.: 32 lead-sponsored trials and 3 legal-entity registrations.
Disease areas (15)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Atrial Fibrillation | 29 |
| Pain | 7 |
| Postoperative Pain | 5 |
| Stroke | 3 |
| Tachycardia | 3 |
Showing 5 of 15 disease areas.
Trials by start year as sponsor or collaborator (19)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 3 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 7 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 2 |
| 2016 | 3 |
Showing 10 of 19 years.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (1)
| Drug | Trials |
|---|---|
| Anticoagulation Therapy | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 25% hit target (n=12) | 10% on time (n=10) |
Journals published in (37)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of pediatric surgery | 5 |
| The Journal of thoracic and cardiovascular surgery | 5 |
| European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery | 3 |
| Heart rhythm | 3 |
| American heart journal | 2 |
Showing 5 of 37 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 200 | 81 | 2025-12-23 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 534,528,000 | -11,448,000 | 99,209,000 |
| 2024 | 465,307,000 | -44,698,000 | 96,178,000 |
| 2023 | 399,245,000 | -30,438,000 | 73,915,000 |
| 2022 | 330,379,000 | -46,466,000 | 57,337,000 |
| 2021 | 274,329,000 | 50,199,000 | 48,506,000 |
| 2020 | 206,531,000 | -48,155,000 | 43,070,000 |
| 2019 | 230,807,000 | -35,194,000 | 41,230,000 |
| 2018 | 201,630,000 | -21,137,000 | 34,723,000 |
| 2017 | 174,716,000 | -26,892,000 | 34,144,000 |
| 2016 | 155,109,000 | -33,338,000 | 35,824,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (9)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-01-09 | Debt financing | not disclosed | Sec extracted |
| 2025-02-14 | Follow-on offering | not disclosed | Edgar offerings |
| 2024-01-05 | Debt financing | not disclosed | Sec extracted |
| 2022-02-17 | Other financing | not disclosed | Edgar offerings |
| 2020-05-13 | Other financing | not disclosed | Edgar offerings |
Showing 5 of 9 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 10 |
FDA recalls (13)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Cryo Module Accessories Domestic CMA-OUS, Product Catalog Number A001053 | Class II | 2023-11-28 |
| Packaged, Tank Hose Assembly CMA-US, Product Catalog Number A001056 | Class II | 2023-11-28 |
| EPi-Sense Guided Coagulation System with Visitrax, MOdel No. CDK-1413 - Product Usage: The EPi-Sense Guided Coagulation System with VisiTrax, consists of a sterile, single-use, disposable coagulation electrode device (1cm, 2cm, and 3cm sizes provided) intended to be used to coagulate cardiac tissue. The flexible, cooled electrode device, with a suction stabilizer feature, transmits radiofrequency (RF) energy from an Electrosurgical Generator (non-sterile, re-useable) connected through an Instrument Cable (sterile). A temporary sensing electrode feature may be used with an off-the-shelf electrogram recording system with the use of an additional instrument cable (non-sterile). An accessory Cannula may be used to facilitate coagulation device access and visibility of the heart. The EPi-Sense Guided Coagulation System with VisiTrax technology is intended for the coagulation of cardiac tissue using Radiofrequency (RF) energy using thoracoscopic, endoscopic, and laparoscopic surgical techniques and may be used for temporary cardiac signal sensing and recording during surgery when connected to a temporary external recording device. | Class II | 2019-05-29 |
| COBRA FUSION 50, Ablation System, Catalog # (REF) 700-002 | Class II | 2019-01-22 |
| COBRA FUSION 150 Ablation System, Catalog # (REF) 700-001 | Class II | 2019-01-22 |
Showing 5 of 13 recalls.
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| ATRICURE, INC. | Mason, US | FDA | |
| AtriCure, Inc. | Pleasanton, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (277)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-09 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-12-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-25 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 277 events.
Biomarker capability evidence (6)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AFF1 | Trial sponsor | Named in trial inclusion criteria |
| NPPB | Trial sponsor | Named in trial inclusion criteria |
| MME | Trial collaborator | Named in trial exclusion criteria |
| AFF1 | Trial sponsor | Mentioned in trial text |
| MME | Trial collaborator | Mentioned in trial text |
Showing 5 of 6 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, fda warning letters, fda untitled letters, fda import refusals, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.